An Exploratory Study on CLU, CR1 and PICALM and Parkinson Disease

Jianjun Gao1, Xuemei Huang2, YikYung Park3, Albert Hollenbeck4, Honglei Chen1*

1 Epidemiology Branch of the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America, 2 Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of America, 3 Nutritional Epidemiology Branch, National Cancer Institute, Rockville, Maryland, United States of America, 4 AARP, Washington, D.C., United States of America

Abstract

**Background:** Recent GWAS and subsequent confirmation studies reported several single-nucleotide polymorphisms (SNPs) at the CLU, CR1 and PICALM loci in association with late-onset Alzheimer’s disease (AD). Parkinson disease (PD) shares several clinical and pathological characteristics with AD; we therefore explored whether these SNPs were also associated with PD risk.

**Methodology/Principal Findings:** 791 non-Hispanic Whites cases and 1,580 matched controls were included in the study. Odds ratios (OR) and 95% confidence intervals (CI) were obtained from logistic regression models. rs11136000 at the CLU locus was associated with PD risk under the recessive model (comparing TT versus CC+CT: OR = 0.71, 95% CI: 0.55-0.92, p = 0.008) after adjusting for year of birth, gender, smoking, and caffeine intake. Further adjustment for family history of PD and ApoE e4 status did not change the result. In addition, we did not find evidence for effect modification by ApoE or known PD risk factors. The association, however, appeared to be stronger for PD with dementia (OR = 0.49, 95% CI: 0.27-0.91) than for PD without dementia (OR = 0.81, 95% CI: 0.61-1.06). The two other SNPs, rs6656401 from CR1, and rs3851179 from PICALM region were not associated with PD (p>0.05).

**Conclusion:** Our exploratory analysis suggests an association of CLU with PD. This exploratory finding and the role of dementia in explaining this finding needs further investigation.

Introduction

Alzheimer’s disease (AD) and Parkinson disease (PD) are the two most common neurodegenerative diseases among the elderly. These two conditions share several clinical and pathological characteristics. For example, they both are clinically progressive and involve abnormal protein depositions [1]. Further, more than half of PD patients eventually develop dementia [2], and conversely, parkinsonian signs are common among Alzheimer patients [3]. Finally, although not entirely consistent [4], preliminary data suggest that individuals with a family history of PD may have a higher risk for AD [5,6,7,8]. These links suggest that AD and PD may have some shared risk factors and/or common pathogenic mechanisms. However, to date, little effort has been made to search for potential genetic or environmental risk factors that may contribute to both diseases.

Recent large genome-wide association studies (GWAS) have reported several novel susceptibility genetic loci for late onset AD, including clusterin (CLU) [9,10], complement component (3b/4b) receptor 1 (CR1) [10] and the phosphatidylinositol binding clathrin assembly protein (PICALM) [9]. These findings were subsequently confirmed in a large pooled sample of AD cases and controls [11]. We therefore explored the relationship of PD with selected SNPs from the AD GWAS studies (rs11136000 for CLU, rs6656401 for CR1, and for rs3851179 for PICALM) in a large PD case-control study.

Results

Table 1 shows population characteristics according to case-control status. As expected, Parkinson patients were less likely to be smokers and drank less caffeinated drinks than controls (p<0.0001). Compared with controls, they were also less likely to be ApoE e4 carriers, but more likely to report a family history of PD. Among Parkinson cases, the average age at onset was 65.7±7.4 years and the average age at diagnosis was 66.6±7.4 years. Approximately 19% of Parkinson patients had dementia as reported by their treating physician or by medical record review, and the prevalence of dementia was higher among Parkinson patients diagnosed before 2000 (23.6%) than those diagnosed after 2000 (13.9%).

All SNPs in controls conformed to Hardy-Weinberg equilibrium (p>0.05). None of the SNPs examined was related to PD risk under the additive models or dominant models; however, rs11136000 at the CLU locus was associated with PD risk under the recessive model (Table 2). After adjusting for year of birth,
When PD cases with and without dementia were analyzed, an association of ApoE ε4 and PD was observed with a statistically significant lower risk of PD (OR: 0.79, 95% CI: 0.61-0.96). However, the association varied by gender: women had a lower risk (OR = 0.76, 95% CI: 0.55-0.95) than men (OR = 0.81, 95% CI: 0.61-1.06). Similar results were observed for cases diagnosed before 2000 (OR = 0.76, 95% CI: 0.55-0.95) and for cases diagnosed after 2000 (OR = 0.69, 95% CI: 0.50-0.95). Subgroup analyses generally showed similar results (Figure 1). The results were also consistent with previous studies that suggested a null association between ApoE ε4 and PD.

### Discussion

In this large case-control analysis, we found preliminary evidence that rs11136000 at the CLU locus might be associated with PD, and this association appeared to be stronger for PD patients with dementia. Our analyses also suggest that this relationship was independent of ApoE or known risk factors for PD.

Several clinical and pathological similarities between PD and AD have led to the hypothesis that these two conditions may share some pathogenic mechanisms or risk factors [1,11]. ApoE ε4, the most established genetic risk factor for AD, has been examined in relation to PD in over 30 case-control studies. Most prior studies reported a null association between ApoE ε4 and PD [13,14], although a few reported either higher or lower PD prevalence among ε4 carriers [15,16,17,18]. We also examined ApoE ε4 in our study sample. We found that while ApoE ε4-carriers had a higher prevalence of dementia than non-carriers among PD patients, ApoE ε4 was associated with a statistically significant lower risk of PD (OR: 0.75, 95% CI: 0.59-0.94) [19]. Although this result needs confirmation from other studies, it is consistent with several previous epidemiological observations that higher plasma cholesterol was associated with a lower risk for PD [20,21,22].

Two recent large GWAS [9,10] have independently identified rs11136000 at the CLU locus as a risk allele for late onset AD, and the findings were subsequently confirmed in a large case-control study and a meta-analysis [11]. Clusterin may have diverse biological functions; however, the exact mechanisms how clusterin affects AD pathogenesis are yet to be unveiled [23,24]. Several hypotheses have been proposed, including actions on amyloid-β deposition or clearance, cell survival, neuroinflammation, or lipid trafficking [23,24]. Some of these biological processes have also been implicated in PD pathogenesis. Direct explorations of potential roles of clusterin in Parkinson pathogenesis are rare. Preliminary evidence suggests that clusterin may affect the formation of Lewy body by acting as a chaperone [25,26]. Further, a recent clinical study found that PD patients had significantly higher levels of clusterin in the cerebrospinal fluid than in controls [27].

An alternative explanation is that the finding was mediated by an association of CLU with PD dementia. In support of this, we found that the association was stronger for PD dementia than for PD without dementia, although both associations were in the same direction. The presence of dementia in our study was collected only as part of PD diagnostic confirmation and thus we were unable to examine this possibility in details. Therefore, if our finding is confirmed, future studies should also investigate the possibility that the association of CLU with PD might be explained by its potential association with dementia.

CLU [10] and PICALM [9] were each implicated in one of the above referenced AD GWAS. CR1 encodes complement receptor 1, and may play a role in neuroinflammation and amyloid clearance [24]. On the other hand, PICALM encodes a ubiquitously expressed phosphatidylinositol-binding clathrin assembly protein which may affect synaptic neurotransmission and trafficking [24]. In our study sample, SNPs selected for these two genetic loci were not associated with PD risk. The later meta-analysis of AD GWAS data [11] found that rs821179 at the PICALM locus was only associated with AD risk among ApoE ε4 carriers.

### Table 1. Population characteristics of Parkinson Cases and controls.

| Variable                        | Case (%) | Control (%) | P value |
|---------------------------------|----------|-------------|---------|
| All                             | 791      | 1580        |         |
| Men                             | 604 (76.4) | 1244 (78.7) |         |
| Women                           | 187 (23.6) | 336 (21.3)  | 0.19    |
| Year of Birth                    |          |             |         |
| 1925-1929                        | 283 (35.8) | 616 (39.0)  |         |
| 1930-1934                        | 264 (33.4) | 558 (35.3)  |         |
| 1935-1939                        | 160 (20.2) | 264 (16.7)  |         |
| 1940-                            | 84 (10.6)  | 142 (9.0)   | 0.07    |
| Smoking status                   |          |             | <.0001  |
| Never                            | 368 (46.5) | 555 (35.1)  |         |
| Former                           | 388 (49.1) | 916 (58.0)  |         |
| Current                          | 24 (3.0)  | 93 (5.9)    |         |
| Missing                          | 11 (1.4)  | 16 (1.0)    |         |
| Caffeine intake (mg/day)         | 296.5±338.0 | 359.8±359.9 | <.0001  |
| Family History of PD             |          |             | <.0001  |
| Yes                              | 112 (14.2) | 86 (5.4)    |         |
| No                               | 672 (85.0) | 1356 (85.2) |         |
| Missing                          | 7 (0.9)   | 138 (8.7)   |         |
| Age at diagnosis (n=781*)         | 66.6±7.4  | NA          |         |
| Age at first symptoms (n=642*)    | 65.7±7.4  | NA          |         |
| Year of diagnosis                |          |             |         |
| Before 2000                      | 363 NA    |             |         |
| 2000 and after                   | 428 NA    |             |         |
| CLU: rs11136000                  |          |             |         |
| CC                              | 281 (35.8) | 569 (36.1)  |         |
| CT                              | 402 (51.2) | 746 (47.3)  |         |
| TT                              | 102 (13.0) | 261 (16.6)  | 0.05    |
| PICALM: rs3851179                |          |             |         |
| GG                              | 298 (38.5) | 631 (40.4)  |         |
| GA                              | 359 (46.3) | 716 (45.8)  |         |
| AA                              | 118 (15.2) | 215 (13.8)  | 0.52    |
| CR1: rs6656401                   |          |             |         |
| GG                              | 522 (66.8) | 1028 (65.5) |         |
| GA                              | 233 (29.8) | 493 (31.4)  |         |
| AA                              | 27 (3.5)  | 48 (3.1)    | 0.66    |
| ApoE: ε4                        |          |             |         |
| ε4 carrier                       | 631 (80.0) | 1166 (75.6) | 0.02    |
| Non-ε4 carrier                   | 158 (20.0) | 376 (24.4)  |         |

Notes: 
*Chi-Square tests for categorical variables, t-tests for continuous variables

*number of participants that provided data.
carriers; our analysis did not reveal a significant interaction between rs3821179, or any other SNPs, and ApoE e4 allele [6].

Unlike clusterin, for which there is preliminary experimental evidence, we are not aware of any evidence suggesting a link between CR1 or PICALM and PD.

To the best of our knowledge, this is the first attempt to examine recent AD GWAS findings in PD pathogenesis. Therefore, our analyses should be considered exploratory and hypothesis generating; accordingly, we explored the associations under different genetic models and did not adjust for multiple comparisons. Although this study is among the larger population based genetic studies on PD, the statistical power was limited. For example, we had only an adequate statistical power for a common SNP (minor allele frequency $38.5\%$) and a moderate association (OR #0.69 or $1.38$) under a recessive model. For this consideration, we only chose the most significant SNPs in previous AD GWAS. Further, it is important to point out that the previous AD GWAS analyses were based on additive model, but our analysis on rs11136000 was only statistically significant under recessive model. Due to these uncertainties, our finding on rs11136000 only suggests a potential link to this genomic locus; future studies with larger sample size and denser SNP coverage are needed to confirm our result, and if confirmed, further investigations would be needed to identify the underlying gene and functional SNPs.

In this study, we confirmed the diagnosis of PD with patients' treating physicians, rather than having the diagnosis uniformly made by study related movement disorder specialists. We therefore could not exclude the possibility of a few misdiagnoses. Nevertheless, recent clinicopathological studies showed a 90% accuracy for PD diagnosis made by clinical neurologists [28]. We were also concerned about the possibility that cohort participants with dementia might have been less likely to participate in this study than participants without dementia. This factor, however, might have similarly affected both cases and controls. Further, results from sensitivity analyses stratified by the year of PD diagnosis or baseline age showed similar results across subgroups. We therefore expect the impact from this bias is likely to be limited. With the same reasoning, we expect that poor health or poor survival of prevalent PD patients might also have limited impacts on the analysis. Finally, the current analysis was conducted among non-Hispanic Whites, therefore the generalizability of these findings to other ethnicities is uncertain.

Methods

Patients

PD cases and controls were from the Parkinson’s, Genes, and Environment (PAGE) study that was nested within the large

| Models | CLU - rs11136000 *b/B = T/C | PICALM - rs3851179 *b/B = A/G | CR1 - rs6656401 *b/B = A/G |
|--------|-----------------------------|-----------------------------|-----------------------------|
| Case/Control | 785/1576$^*$ | 775/1562$^\\circ$ | 782/1569$^\#$ |
| Additive Model 1 | 0.92 (0.81, 1.04) | 1.07 (0.94, 1.21) | 0.99 (0.84, 1.16) |
| Model 2 | 0.91 (0.80, 1.04) | 1.08 (0.95, 1.23) | 0.99 (0.84, 1.16) |
| Dominant/ (Bb+bb) vs BB Model 1 | 1.00 (0.84, 1.20) | 1.07 (0.89, 1.28) | 0.96 (0.80, 1.16) |
| Model 2 | 0.98 (0.82, 1.18) | 1.10 (0.91, 1.32) | 0.95 (0.79, 1.15) |
| Recessive/ bb vs (BB+Bb) Model 1 | 0.71 (0.55, 0.92) | 1.13 (0.88, 1.45) | 1.15 (0.71, 1.87) |
| Model 2 | 0.74 (0.57, 0.95) | 1.13 (0.88, 1.45) | 1.27 (0.77, 2.09) |

$b$: minor allele; $B$: major allele; $^*$ numbers of participants to be genotyped successfully.

Model 1: logistic models adjusted for year of birth, gender, smoking status, and daily caffeine intake.

Model 2: further adjusted for family history of PD and ApoE e4 status (e4 carrier and Non-e4 carrier).

doi:10.1371/journal.pone.0024211.t002

Figure 1. Stratified analysis of the relationship between rs11136000 and PD based on the recessive model (TT vs TC/CC), adjusted for year of birth, gender, smoking status, and daily caffeine intake. None of the interactions were statistically significant.

doi:10.1371/journal.pone.0024211.g001
prospective cohort: the National Institute of Health (NIH)-AARP Diet and Health Study cohort (Formerly known as American Association of Retired Persons. [29]). This cohort was established in 1995-1996 for research on cancer and other chronic diseases and collected detailed dietary and lifestyle data at baseline [29]. Potential PD patients in this cohort were identified from self-reports in the cohort’s follow-up survey in 2004-2006, which asked participants whether they had ever been informed by a doctor that they had PD. We then contacted surviving self-reported cases to verify the diagnosis and to collect saliva samples for genetic analysis. Detailed procedures for case confirmation were published previously [30]. Briefly, we first obtained confirmation and permission from self-reported PD patients and then contacted their treating physicians to complete diagnostic form and a copy of the relevant medical record. As part of this clinical data collection, we also collected information on the dates of first symptoms and diagnosis, the presence of dementia, and the family history of PD among first degree biological relatives. The Parkinson case was confirmed if the diagnosis was either validated by the patient’s treating physician or by medical record review showing a final PD diagnosis or at least two cardinal signs of PD with one being resting tremor or bradykinesia, a progressive course, and the absence of unresponsiveness to levodopa or other features suggesting an alternative diagnosis. Only physician confirmed PD cases (86.7% by neurologist and movement disorder specialists) were included in the analysis. A similar procedure was successfully used in other large cohorts [31,32,33]. Potential controls were randomly selected from cohort participants who did not report PD in the follow-up survey, frequency matched to self-reported cases on year of birth, gender, and ethnicity. Saliva samples were obtained from cases and controls in the cohort’s follow-up survey in 2004-2006, which asked participants whether they had ever been informed by a doctor that they had PD. We then contacted surviving self-reported cases to verify the diagnosis and to collect saliva samples for genetic analysis. Detailed procedures for case confirmation were published previously [30]. Briefly, we first obtained confirmation and permission from self-reported PD patients and then contacted their treating physicians to complete diagnostic form and a copy of the relevant medical record. As part of this clinical data collection, we also collected information on the dates of first symptoms and diagnosis, the presence of dementia, and the family history of PD among first degree biological relatives. The Parkinson case was confirmed if the diagnosis was either validated by the patient’s treating physician or by medical record review showing a final PD diagnosis or at least two cardinal signs of PD with one being resting tremor or bradykinesia, a progressive course, and the absence of unresponsiveness to levodopa or other features suggesting an alternative diagnosis. Only physician confirmed PD cases (86.7% by neurologist and movement disorder specialists) were included in the analysis. A similar procedure was successfully used in other large cohorts [31,32,33]. Potential controls were randomly selected from cohort participants who did not report PD in the follow-up survey, frequency matched to self-reported cases on year of birth, gender, and ethnicity. Saliva samples were obtained from cases and controls using Oragene™ saliva collection kits (DNA Genotek Inc., Ontario Canada). For controls, family history of PD was asked as part of the saliva collection. A total of 838 physician confirmed PD cases and 1,703 controls were genotyped for the current analyses. To avoid population stratification, we excluded 30 cases and 80 controls who were not non-Hispanic Whites or had missing information on ethnicity. We further excluded 17 cases and 43 controls who failed genotyping on all three SNPs, leaving us a total of 791 cases and 1,580 controls for the final analyses. The study protocol was approved by the Institutional Review Board of the National Institute of Environmental Health Sciences with written consent from all study participants.

**Exposure Assessment**

The baseline questionnaire of the NIH-AARP Diet and Health Study collected detailed data on diet, lifestyle, and population demographics, including birth date, gender, and ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Asian, Pacific Islander, or American Indian/Alaskan Native) [29]. In addition, we asked participants to report whether they had ever smoked more than 100 cigarettes during their lifetime; and for “ever smokers”, we further asked for the typical amount of smoking, current smoking status and years since last smoking. Daily caffeine intake was derived from the baseline dietary survey.

**DNA extraction and genotyping**

DNA was extracted from saliva samples collected with the Oragene™ collection kits. Three SNPs were selected based on their statistical significance as reported in the GWAS, one for each gene region: rs11136000 for CLU, rs6656401 for CR1, and rs3851179 for PICALM. One additional SNP on PICALM was also selected based on information from ALZgene.com; this SNP is in linkage disequilibrium with rs3851179 and the results were also similar, so we did not present detailed data for that particular SNP. Genotyping was performed by BioServe Biotechnologies, Ltd., Beltsville, MD, using MassARRAY iPLEX™ platform (Sequenom, San Diego CA). Sequenom is a PCR and mass spectrometry based system. Genotyping assays are custom developed using Mass ARRAY Assay Design 3.1 software. For quality control purpose, we randomly included 51 duplicated saliva DNA samples which were kept blinded to the genotyping laboratory; the genotyping reproducibility was 100%.

**Statistical analyses**

We examined Hardy-Weinberg equilibrium with chi-square statistics. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression models, adjusting for year of birth (in four groups), gender, smoking status (never, former, current) and daily caffeine intake (quintile). We also further adjusted for family history of PD and ApoE ε4 status. We examined each individual allele in relation to PD first under an additive model and then under dominant and recessive models. We began the analyses with all participants, and then stratified by individual covariates: year of birth (below or above median), gender (men vs. women), smoking status (never vs. ever smokers) caffeine intake (below or above median), family history of PD (Yes vs. No), and ApoE ε4 status (ε4 carriers vs. non-ε4 carriers).

To examine the potential influence of bias stemming from the possibility that PD cases with dementia were less likely to participate in the study than PD cases without dementia, we conducted a sensitivity analysis to examine the association of genes with PD separately for cases diagnosed before the year 2000 and diagnosed after the year 2000. We assumed that cases with longer duration of PD (e.g. diagnosed before 2000) were more likely to have dementia than cases with shorter duration, and therefore such a bias would affect the analyses for cases with years of PD more so than for recent cases. With the same reasoning, stratified analysis by age may also help clarify the potential influence of dementia as the prevalence of dementia increases dramatically with age. Finally, we also analyzed rs11136000 at the CLU locus separately in relation to PD with dementia and PD without dementia. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC) combined with Plink v1.07. Post-hoc power calculation was performed with Quanto V1.2.4 [34]. Two sided p<0.05 was considered statistically significant.

**Acknowledgments**

The authors wish to thank all the participants of the National Institute of Health (NIH)-AARP Diet and Health Study cohort. We also thank the editor and the anonymous reviewers for their constructive comments, which are very helpful for strengthening the presentation of this study.

**Author Contributions**

Conceived and designed the experiments: HC. JG. Analyzed the data: JG. Wrote the paper: HC. JG. Collected data: HC XH YP AH. Acquired funding: HC. Reviewed and revised the paper: HC JG XH YP AH. Supervised the study: HC. Wrote the paper: HC JG.

References

1. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl): S10–17.
2. Caballol N, Marti MJ, Tolosa E (2007) Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22(Suppl 17): S358–366.
3. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schnieder JA, et al. (2000) Progression of parkinsonian signs in Alzheimer’s disease. Neurology 54: 1284–1289.
4. Levy G, Louis ED, Mejias-Sanchez H, Cote L, Andrews H, et al. (2004) Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 61: 1033–1039.
5. Hofman A, Schulte W, Tanja TA, van Duijn CM, Haaxma R, et al. (1989) History of dementia and Parkinson’s disease in 1st-degree relatives of patients with Alzheimer’s disease. Neurology 39: 1389–1392.
6. Costello S, Bordelon Y, Bronstein J, Ritz B (2010) Familial associations of Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol 17: 671–676.
7. Rosen AR, Sterenland NK, Hanfelt J, Factor SA, Lah JJ, et al. (2007) Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history. Neurogenetics 8: 263–270.
8. Marder K, Tang MX, Alfaro B, Mejia H, Cote L, et al. (1999) Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia. Neurology 52: 719–724.
9. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
10. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41: 1094–1099.
11. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, et al. (2010) Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67: 1473–1484.
12. Hughes AJ, Daniel SE, Lees AJ (1995) The clinical features of Parkinson’s disease in 100 histologically proven cases. Adv Neurol 60: 595–599.
13. Huang X, Chen PC, Poole C (2004) APOE-[epsilon] allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62: 2188–2202.
14. Williams-Gray CH, Gorsis A, Sasaki M, Foltynie T, Compston DA, et al. (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 256: 493–498.
15. Blazquez L, Otadui G, Saenz A, Paisan-Ruiz C, Empananza JI, et al. (2006) Apolipoprotein E e4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett 406: 235–239.
16. Ghebremedhin E, Del Tredici K, Vukic M, Rub U, Thal DR, et al. (2006) Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 65: 116–123.
17. Group TFPDGS (1997) Apolipoprotein E genotype in familial Parkinson’s disease. The French Parkinson’s Disease Genetics Study Group. J Neurol Neurosurg Psychiatry 63: 394–395.
18. Papapetropoulos S, Farrer MJ, Stone JJ, Milkovic NM, Ross OA, et al. (2007) Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 414: 141–144.
19. Gao JJ, Huang XM, Park Y, Liu R, Hollenbeck A, et al. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging. (In press).
20. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW (2008) Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 23: 1013–1018.
21. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2006) Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol 164: 998–1002.
22. Simon KG, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69: 1608–1615.
23. Nunninen T, Suuronen T, Kauppinen A, Salmiinen A (2009) Clusterin: a forgotten player in Alzheimer’s disease. Brain Res Rev 61: 89–104.
24. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, et al. (2010) The pursuit of susceptibility genes for Alzheimer’s disease: progress and prospects. Trends Genet 26: 84–93.
25. Sasaki K, Doihara K, Wakiyama Y, Iwaki T (2002) Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol 104: 225–230.
26. Carreras I, Garret-Young R, Ullman MD, Eisenhauer PB, Fine RE, et al. (2005) Upregulation of clusterin/apolipoprotein J in lactacystin-treated SH-SY5Y cells. J Neurosci Res 79: 499–502.
27. Pekrylova Vranova H, Mares J, Neely M, Stejskal D, Zapletalova J, et al. (2010) CSF markers of neurodegeneration in Parkinson’s disease. J Neural Transm 117: 1177–1181.
28. Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57: 1497–1499.
29. Schadt E, Subar AF, Thompson FE, Harlan LC, Tangrea J, et al. (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119–1125.
30. Chen H, Huang X, Guo X, Mailman RB, Park Y, et al. (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74: 878–884.
31. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, et al. (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50: 56–63.
32. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, et al. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58: 963–967.
33. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A (2002) Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol 52: 795–801.
34. Gauderman W, Morrison J QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/ gxe.